表皮生长因子受体敏感突变肺癌靶向治疗原发性耐药机制的研究进展  

The research progress in the mechanism of primary resistance in targeted therapy for lunng cancer with epidermal growth factor receptor-sensitive mutations

作　　者：张译丹 钟润波[1] Zhang Yidan;Zhong Runbo(Department of Respiratory,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China)

机构地区：[1]上海市胸科医院/上海交通大学医学院附属胸科医院呼吸内科,上海200030

出　　处：《中华转移性肿瘤杂志》2024年第1期88-92,共5页Chinese Journal of Metastatic Cancer

基　　金：上海市2020年度“科技创新行动计划”医学创新研究专项(20Y11913800)。

摘　　要：针对伴有表皮生长因子受体(EGFR)敏感突变的晚期非小细胞肺癌, 小分子靶向药物表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗效果明确, 是目前的标准治疗方法。然而, 部分患者在初始治疗时即出现原发性耐药。本文就EGFR敏感突变的晚期非小细胞肺癌患者原发性耐药可能机制展开讨论与总结, 以期为临床治疗决策提供参考。Small molecule targeted drug epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)have been established as the standard treatment for advanced non-small cell lung cancer(NSCLC)with EGFR sensitive mutations.Nevertheless,a subset of patients exhibit primary resistance to EGFR-TKIs during initial therapy.This review aims to summarize the potential mechanisms underlying primary drug resistance in advanced NSCLC patients with EGFR sensitive mutations,with the intention of offering valuable insights for clinical treatment strategies.

关 键 词：表皮生长因子受体敏感突变 酪氨酸激酶抑制剂 原发性耐药 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]